Fintel reports that on October 17, 2025, B of A Securities maintained coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a ...
Zacks Investment Research on MSN
CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know
In the latest close session, CRISPR Therapeutics AG (CRSP) was down 6.54% at $68.29. The stock trailed the S&P 500, which registered a daily gain of 1.56%. On the other hand, the Dow registered a gain ...
Another ETF that looks well positioned to outperform the S&P 500 again in 2026 is the Invesco QQQ Trust. It tracks the Nasdaq ...
CRISPR Therapeutics AG (CRSP) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
CRISPR Therapeutics (CRSP) has filed a prospectus supplement with the U.S. SEC to sell up to $600 million worth of its common ...
Zacks.com on MSN
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know
CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $74.89, moving 2.46% from the previous trading session.
Investors in CRISPR Therapeutics AG (Symbol: CRSP) saw new options become available this week, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback